<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477604</url>
  </required_header>
  <id_info>
    <org_study_id>MMS-001</org_study_id>
    <nct_id>NCT03477604</nct_id>
    <nct_alias>NCT04025008</nct_alias>
  </id_info>
  <brief_title>A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)</brief_title>
  <official_title>A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Micro Medical Solution, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Micro Medical Solution, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus
      the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and
      effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred
      to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with
      peripheral arterial disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patency of the target lesion</measure>
    <time_frame>up to 6 months after randomization</time_frame>
    <description>Primary patency defined as freedom from target lesion occlusion with no clinically driven target lesion reintervention, or major amputation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from perioperative death</measure>
    <time_frame>up to 30 days after randomization</time_frame>
    <description>Freedom from perioperative death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from major adverse limb event</measure>
    <time_frame>up to 6 months after randomization</time_frame>
    <description>Freedom from major adverse limb event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from major amputation above the ankle</measure>
    <time_frame>up to 6 months after randomization</time_frame>
    <description>Freedom from major amputation (above the ankle)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in size of ischemic leg/foot ulcers</measure>
    <time_frame>up to 6 months after randomization</time_frame>
    <description>Reduction in size of ischemic leg/foot ulcers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from major adverse limb event</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 36 months</time_frame>
    <description>Freedom from major adverse limb event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of serious adverse events and device and procedure related adverse events</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 36 months</time_frame>
    <description>Frequency and severity of serious adverse events and device and procedure-related adverse events at any time during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>MicroStent and Standard PTA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MicroStent and Standard PTA</intervention_name>
    <description>Self-expanding stent and standard PTA balloon</description>
    <arm_group_label>MicroStent and Standard PTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard PTA</intervention_name>
    <description>Standard PTA balloon</description>
    <arm_group_label>Standard PTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. Subject is a male or a non-pregnant female adult between the age of 21 and 90 years
             old.

          2. Subject has documented clinical evidence of critical limb ischemia (CLI) in the target
             limb prior to the index procedure, with a Rutherford Classification score of 4-5.

          3. The subject, or subject's designated legal representative, has been informed of the
             nature of the study and is willing to provide written informed consent.

          4. Subject is willing to comply with all required follow-up visits.

          5. Subject life expectancy is ≥1 year per the Principal Investigator.

             Angiographic Inclusion Criteria

          6. Target vessel reconstitutes at or above the ankle with inline flow to at least one
             patent (&lt;50% stenosis) inframalleolar outflow vessel.

          7. Subject has a lesion, with ≥ 70% stenosis and ≤ 12.0 cm in length located at or distal
             to the tibial-peroneal trunk and above the tibiotalar joint; including the anterior
             tibial, posterior tibial or peroneal arteries.

          8. Target lesion has a reference vessel diameter of 2.5 - 4.5 mm

          9. The target lesion is able to be crossed with a guidewire to facilitate treatment with
             the randomized device.

        General Exclusion Criteria:

          1. Subject had a prior or has a planned index limb amputation above the ankle.

          2. Subject has a wound/ulcer on the forefoot with a surface area &gt;4cm² or osteomyelitis
             involving the calcaneus bone.

          3. Subject is pregnant, plans to become pregnant, or is nursing.

          4. Subject has clinical conditions that severely inhibit X-ray or duplex ultrasound
             visualization (e.g. body habitus).

          5. Subject has a history of hypercoagulation/clotting disorders or acute thrombosis.

          6. Subject has allergy to iodinated contrast media that cannot be adequately managed with
             medication.

          7. Subject is in acute renal failure.

          8. Subject has an active systemic infection.

          9. Subject is participating in another research study involving an investigational
             device, biologic, or drug that has not completed the primary endpoint at the time of
             randomization/enrollment.

         10. Subject has other comorbidities that - in the opinion of the investigator - preclude
             them from receiving study treatment and/or from completing the required study
             follow-up assessments.

         11. Subject presents with acute limb ischemia or acute thrombosis of the target limb.

         12. Subject has experienced myocardial infarction, thrombolysis, or angina less than 30
             days prior to the index procedure.

         13. Subject had a stroke within 3 months of index procedure.

             Angiographic exclusion criteria

         14. Failure to successfully treat clinically significant inflow lesions in the ipsilateral
             iliac, femoral, or popliteal arteries. Successful treatment is defined as obtaining
             ≤30% residual stenosis with no major procedural complications (e.g embolism).

         15. Failure to successfully treat significant non-target infra-popliteal lesions.
             Successful treatment is defined as obtaining ≤30% residual stenosis with no major
             procedural complications (e.g. embolism).

         16. Target lesion is within a previously placed stent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kate Mandall</last_name>
    <phone>949-292-5466</phone>
    <email>kmandall@micromedicalsolutions.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Associates of the Southeast</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tammy Stover</last_name>
    </contact>
    <investigator>
      <last_name>Jan Skowronski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Modern Vascular</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denisse Martinez Gaspar</last_name>
      <email>dmartinez@modernvascular.com</email>
    </contact>
    <investigator>
      <last_name>Scott Brannan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hudson</last_name>
      <phone>904-493-3333</phone>
      <phone_ext>1049</phone_ext>
      <email>mhudson@firstcoastcardio.com</email>
    </contact>
    <investigator>
      <last_name>Vaquar Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gimeno</last_name>
      <email>Jennifer.Gimeno@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Robert Beasley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advent Health Sebring</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33872</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Leicht</last_name>
      <email>James.Leicht@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Shimshak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush Universtiy Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl Villaneuva</last_name>
      <phone>312-563-7305</phone>
      <email>Karl_Villanueva@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Bulent Arslan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evansville Surgical Associates</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Foncannon</last_name>
      <phone>812-424-8231</phone>
      <phone_ext>212</phone_ext>
      <email>tara.foncannon@evansvillesurgical.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Langenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Shammas</last_name>
      <email>shammasw@mcrfmd.com</email>
    </contact>
    <investigator>
      <last_name>Nick Shammas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vascular Institute of the Midwest</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynn Jarrett</last_name>
      <phone>563-324-3818</phone>
      <email>lynn.jarrett@vimidwest.com</email>
    </contact>
    <investigator>
      <last_name>Eric Dippel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deanna Benoit</last_name>
      <email>Deanna.Benoit@cardio.com</email>
    </contact>
    <investigator>
      <last_name>Craig Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Nordstrom</last_name>
      <email>knordstrom@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Khanjan Nagarsheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiac and Vascular Amputation Prevention Centers</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Finton</last_name>
      <email>sfinton@acvcenters.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Saab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastlake Cardiovascular</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosanno Talampas</last_name>
      <email>rtalampas@eastlakecv.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew McElvarr</last_name>
    </contact>
    <investigator>
      <last_name>Rich Kovach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Jersey Vascular Center</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debra Helmer</last_name>
      <email>Deborah.helmer@americanendovascular.com</email>
    </contact>
    <investigator>
      <last_name>John Rundback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Palermo</last_name>
      <phone>919-745-0750</phone>
      <email>rebecca.palermo@unchealth.unc.edu</email>
    </contact>
    <investigator>
      <last_name>George Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health Riverside Methodist</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Belcher</last_name>
      <email>christina.belcher@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>John Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Einstein Heart &amp; Vascular</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Murphy</last_name>
      <phone>215-456-1959</phone>
      <email>murphyra@einstein.edu</email>
    </contact>
    <investigator>
      <last_name>Jon George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori DeSimone</last_name>
    </contact>
    <investigator>
      <last_name>Peter Soukas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Vascular Access and Imaging Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37919</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Rushing</last_name>
    </contact>
    <investigator>
      <last_name>George Pliagas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Solis</last_name>
      <phone>903-595-2283</phone>
      <phone_ext>2102</phone_ext>
      <email>asolis@CAET.net</email>
    </contact>
    <investigator>
      <last_name>Jeff Carr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZH/WAVE Vascular Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taha Siders, MD</last_name>
    </contact>
    <investigator>
      <last_name>Awais Siddique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2018</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Below the knee</keyword>
  <keyword>Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

